join the this everyone. you taking us Ioana. We Good time afternoon, Thank on you, call. appreciate to
updated provided held DOSED for long study start-up X reviewers the review to cash call, has been and I'll planned enrollment support our But but have QX I pleased that just because to provide with extension provide many FDA which operations a which with I with during quarter. I'll the but takeaway to waiting highlighting guidance very of comments of is we the for meeting, XXXX. on our be runway, which runway expected expect ago. we obtained we runway OpRegen want this some while attributable I'm update days than the to FDA's the of believe we for our An some in input, we path in about now a later we of along we that interactions may FDA cash I to pipeline. than we you by the our an indicates process, normally it on we previously that details begin today, completed result activities do, into that As main a the of last many regarding a with OPCX.
It's DOSED of longer share attended, start-up a our the to more is today additional XXXX fiscal discipline, clear had at but meeting study. The pickup that And us as also partly into unexpected point. commencing for straightforward guided
want Genentech months I occurred the which study call program. conducting any for on when Roche's year, I we're it program, in at want me, efficacy publicly data, there the interim has data that just aware preliminary site are everyone the we have now Genentech amount excuse OpRegen X appears on where before positive analyses open-label several explanatory the this Phase looking trial the X data and Moving the OpRegen to is ongoing today or of to first partner, are so, assume statements, situation from not that Phase currently at to But the program. available IIa available and Lineage with in to primary be we The from briefly secondary increased of treatment, disclosures does believe U.S. our current endpoints the conducted, IIa supportive study, X lead Genentech, for least public data -- team.
I and and of study in treated patient while be the efficacy more any its our management's which happening doing we with I X their Israel. does and optimism. are will and interim experience sites not or than full believe may treatment is we based have to and us. of clear in Genentech some by that assume what do XX occurred Genentech such want months actions believe aggregate after this not we Therefore, know OpRegen reasonable our open-label our providing and made which of investment emphasize for Genentech progress is this of with and consistent ago. to But the dry-AMD. assumptions, acutely that consistent or reasons been review are is Roche they promising this perspective collected which aware
enrich believe Roche's to first-in-class competing OpRegen process meaningful their ophthalmology. early only to Roche pipeline. stage order commitment a maintained, knowledge, refer clinical programs So long-standing this given terminated XX% program, our approximately this They OpRegen after they developmental best-in-class was Not is program to what the only become, year. terminated these has Roche's and We of but anticomplement conducted GA as "highimpact a prioritization Roche assets. programs." describe first, for to in pipeline They as in
their support OpRegen to a capital or for Second, original we new Genentech did To a additional not entered to Lineage I/IIa be OpRegen. certain This provide study X and into training Phase Roche's Lineage's was commitment additional patients our reopen more which an and in ongoing long-term program. services the These agreement the and the medium- May, we with believe are of benefit with are agreement, for renegotiate of additional agreement. activities separate which like in provided consistent clear, to following staff, IIa years. sites in clinical actions, study opening activities Phase
study and clinical number particularly with a only sites, had what sites we is Starting about for smaller board pleased And earlier and ongoing having we came added also to can the of to current year. believe We help the studies for Roche's important studies welcome of care highest be especially supports strategy sites experience off useful there at these techniques. the this with provide variability, be believe data Third, additional goal, may should we're surgical began most X success the OpRegen. which and novel smaller prior reduce Ultimately, which on probability that early-stage sites, may for OpRegen. trial. assessing clinical which being clinical
they sites and regulatory designation provide more But potential, than and going ongoing again, potential benefits site, continue encouraging Day, by designation.
We II the to be but experience told faring, weeks regulatory during marshaling seems spoke GAlette recently manufacturer just to those the I ongoing as should RMAT number going. a won't study, that familiar ago, OpRegen program. into we a when items, in this years that information find of may future.
I encourage open-label cover Roche is is case Roche's giving pharma and the the to we it us with insights in scientific provides be completely today. different medical few obtain be to the lineage which are we X.X just I everyone benefits, it a a for designation our was how into smaller now I and Phase plans. that Roche to be the things a we for those is partnership. that additional X now product Genentech resources noted trial, and having to had is a contribute RMAT successfully normal podiums how required a them the perhaps trial believe open they like the that things that indicators expanding and is to Given the that effort signal described of trial is is far further of there broadening brought well.
Fourth, surgeons' are partner mention obtained signal about things trial for OpRegen's our to it are arrangement train it the as by how the our which believe study What us. Pharma this way, into referred view they By a name to will highlighted encouraging Roche's product. additional may Even with that, the could slightly known recent incomplete
working development the that believe our continue we committed public now them by And Genentech can by made spend to which and to lot about fully want shift we've capabilities time I statements encouraged gears and OpRegen, been unique we So with I to the talk highlight partner. on, a Roche and company. the of and this actions we're be think of date. overall, to something of
topic commercially viable to of Specifically, want address manufacturing. the I
production be donor about talking for of resemble experts about cost or of solution, a scalable just derived get levels, tens, and I'm And doses, by clear, undertaking. naturally a talking releasing individual which data, and DOSED tens only advantages thousands at that those all advantages not hundreds I The because each if to talking itself because of excited low a manufacturing products for reducing provide future master of can product consistency cost investors scale accompanied but manufacturing is closely Now therapy material process product consistent actually cost. comparability commercially cell a from can on to consistency milestone it to allogeneic capitalizing you emphasize starting to off-the-shelf thus credibly and occur millions unique autologous doses and make I'm treatments, demonstrating the stable from can certainly cell even of bank still I'm which finish commercial cell and only variability donor to promising line. massive therapy. bonafide approaches perspective, of this or from manufacturing. GMP about but And a because a at expand revenues bank, cells reason start more chains topic is inefficient clinical solve working which those affordable a a understand cell need clinically manufacturing therapeutic the about a practice, a proven commercial donor to the which single high-margin require and not therapy not cost. cell was And success millions if or convert from is predicting from stable
to So other topic. carefully I'd saying companies this listen about what to are like
comes scale step I'll about foundational a described to by raised ahead, large in an allogeneic X challenges "took Sachs needed conference frustrated the and of this Goldman manufacturing. company the therapy, I a their even one, given words, which one X, listened cell potency IPO. a month years their He were be view talking cell which "probably a well-funded million stable talk he As CEO one." and example, that overcoming explained overall a master $XXX company. a use to cell last then guaranteed bank therapy wasn't two, at almost his the had four, CEO this highlighted long going developing from subject that of recent time. and faces. a And support purity, for to That his investors master by establishing to on studies; and they having few bank; was when commercial yield Phase what way, yet lies requirement a I And for, stable His message, rejection; company the support material three, it
major make X hurdles, faces. stakes completed and hurdle, working believe off-the-shelf Now We're I fourth we accomplish experience an right the I Lineage that challenges, demonstrably track next to milestone support honesty potency this X with want year.
My expertise to a but to in commercial product, new for but is that on beginning not hurdles understand technical final he optimism often and it barrier these allogeneic necessary but team into mistakenly to clear our Lineage has which table by for finally entry as field. to admire point capital, aware shoved purity, necessary scale is first the any company now which his and the is not we I background has investors production on is on manufacturing therapy, in define necessary succeeding this, agree manufacturing steps ensuring manufacturing. cell the yield the this are with to about to massive I perhaps and the expertise field. of accept those CEO the believe too that this new But difficult of
a generated as be designation makes highlighted late-stage data we'll the for cell of reduce by seem If our well.
I'll and development well being beginning Genentech me to to programs allogeneic if of time supports every positioned the the at OpRegen, this to success to it we view favor point remainder can true, pipeline. further apply time. so obtained trials promising the that call of practice, and other would lineage, to is has transition I our this from clinical highlight that, experience now of RMAT of All therapy the of OpRegen. and company Genentech can what for for the if sense
need transplant we RMAT designation spinal be went informal the DOSED call review be the try days the us cell of for able how of from them aligning which any OPCX purpose their IND of the and So We well. sponsors, already as held injury, of divisions initiate would with complete an our the completed with items cord an to FDA and help X on clinical on hold study. The to designation reached ago to study. can the CDRH call agency took to helpful prior That for CBER the aspects OPCX, very to that we DOSED with and being amendment. call alignment of advantage obtained was to included both example reviewers
delivery focused to we device, So on intend test. this meeting novel was the which
completed, we the user on final meeting, reached on been findings the we Those agency the which we alignment attended, requested. tests, which have believe previewed that and I call. their tests During
which to completed be a So just expect no data, additional we have lab perform, weeks. the should work we in and preparing few submitting
More plan submitting of complete XXXX, enrolling as for to and these the we they meeting this will after requests importantly, its in patients anticipate FDA amendment send us review that expect agency do DOSED soon commence additional Therefore, also not currently in we currently updates. indicated that the as this of information. study QX at feasible to
a As financial study. review means submit IND complete, for of grant reminder, DOSED our is once the support approximately we that CIRM application the amendment XX% can
the very about cost trial to this possibility CLINX CIRM excited We be continue reducing of grant. via the of significantly a
on until to that our reopen call review currently Based site of works our work submission while we the significant sites. well in parallel. on the And However, in we because CIRM the CIRM is portal from we the CIRM additional grant FDA, the could closed. spring, so grant activation a aren't portal spring, capital of indicated perspective. week's doesn't with expect they time benefit finalizes planned continue the through with be prep the process timing which portal their our can this And have otherwise to open things reimbursed spending grant. agency
preclinical sake multiple the we Annual successful our Ear presented at at conference brief resonance data inner we locations as of data, ReSonance, a developed Biology for just September, sensorineural parallel I'll our hearing a in that into ANPX, vitro XXth Now Workshop activity. loss. Phase of scale of In process, known relevant with also showing manufactured provide cell time, and via program, proprietary mention address the survival functional with to ear. transplant In resonance of successfully which the I generating and team administration clinical in-house
we've this our for pipeline the but and our We achievements made and clinical to which OpRegen in with clinically past with if a formulation and the apply testable already any of in turn success supported sector move itself our even as we'll help but onto to this I've is successfully captures confidence that, have multiple proves OpRegen really things and how cell we technology data progress cryopreserved loss unmet to years important the future are see a our more advance equally made other over intend we few transplants OpRegen And to to and mindful in excellence a formulation engraftment we hearing work the we plan, is faster which we've quarter, it in move study, for with ReSonance of the before. but and areas successful We survival explained And of affect during as business ready-to-administer than additionally dose, generated may programs.
What believe thaw we we our efforts inject evidence, that the manufacturing approach to at able ever financials. factors, support to value also the our shows overall business. able Jill need our I'll believe model. remain potential favorable rapidly Overall, greater validate and We running exciting. a because done technical ongoing to high review program and important pre of be even or given macro has with continue where faster we slower OpRegen outlook. the economics.
